Test | Non sentinel node involvment | ||||
---|---|---|---|---|---|
Class | All (n = 443) | No (n = 358) | Yes (n = 84) | p-value | |
Age | Median [range] | 59 [33–84] | 59 [33–84] | 59 [39–84] | 0.828 |
<= 40 | 26 (5.87) | 24 (6.70) | 2 (2.38) | 0.2864 | |
41–75 | 391 (88.26) | 314 (87.71) | 76 (90.48) | ||
> 75 | 26 (5.87) | 20 (5.59) | 6 (7.14) | ||
Clinical T stage | T1 | 261 (59.32) | 216 (60.67) | 44 (53.01) | 0.2384 |
T2 | 156 (35.45) | 123 (34.55) | 33 (39.76) | ||
T3 | 9 (2.05) | 5 (1.40) | 4 (4.82) | ||
T4 | 2 (0.45) | 2 (0.56) | |||
Tis/Tx | 12 (2.73) | 10 (2.81) | 2 (2.41) | ||
Tumor size (mm) | Median [range] | 18 [0–80] | 18 [0–70] | 19 [0–80] | 0.059 |
<=10 | 64 (14.61) | 55 (15.58) | 9 (10.71) | 0.0465 | |
10–30 | 331 (75.57) | 269 (76.20) | 61 (72.62) | ||
> 30 | 43 (9.82) | 29 (8.22) | 14 (16.67) | ||
Histology Type | Infiltrating ductal | 358 (80.81) | 290 (81.01) | 67 (79.76) | 0.4021 |
Infiltrating lobular | 45 (10.16) | 33 (9.22) | 12 (14.29) | ||
Mixed | 13 (2.93) | 11 (3.07) | 2 (2.38) | ||
Other | 27 (6.09) | 24 (6.70) | 3 (3.57) | ||
SBR Grade | Gr I | 101 (23.60) | 88 (25.51) | 12 (14.63) | 0.1104 |
Gr II | 207 (48.36) | 162 (46.96) | 45 (54.88) | ||
Gr III | 120 (28.04) | 95 (27.54) | 25 (30.49) | ||
LVI | No | 134 (31.60) | 100 (29.41) | 34 (40.96) | 0.0425 |
Yes | 290 (68.40) | 240 (70.59) | 49 (59.04) | ||
Capsular Effraction | No | 327 (80.74) | 276 (83.64) | 50 (67.57) | 0.0016 |
Yes | 78 (19.26) | 54 (16.36) | 24 (32.43) | ||
Hormonal receptors | Negative | 44 (10.16) | 36 (10.32) | 8 (9.64) | 0.8546 |
Positive | 389 (89.84) | 313 (89.68) | 75 (90.36) | ||
HER2 status | Negative | 369 (86.42) | 297 (86.34) | 71 (86.59) | 0.9530 |
Positive | 58 (13.58) | 47 (13.66) | 11 (13.41) | ||
Tumor subtype (RH/HER2) | RH+/HER2+ | 41 (9.72) | 34 (10.00) | 7 (8.64) | 0.8656 |
RH+/HER2- | 339 (80.33) | 272 (80.00) | 66 (81.48) | ||
RH-/HER2+ | 16 (3.79) | 12 (3.53) | 4 (4.94) | ||
RH-/HER2- | 26 (6.16) | 22 (6.47) | 4 (4.94) | ||
Harvested SN, number | Median [range] | 2 [0–7] | 2 [0–7] | 2 [0–5] | 0.650 |
0 | 2 (0.45) | 1 (0.28) | 1 (1.19) | 0.4885 | |
1 | 168 (37.92) | 138 (38.55) | 30 (35.71) | ||
> 2 | 273 (61.63) | 219 (61.17) | 53 (63.10) | ||
Involved SN | Median [range] | 1 [0–4] | 1 [0–4] | 1 [0–4] | 0.004 |
<=2 | 424 (98.60) | 346 (99.43) | 77 (95.06) | 0.0026 | |
> 2 | 6 (1.40) | 2 (0.57) | 4 (4.94) | ||
ITC | 22 (5.30) | 21 (6.19) | 1 (1.33) | 0.0005 | |
SN status | Micro | 137 (33.01) | 124 (36.58) | 13 (17.33) | |
Macro | 256 (61.69) | 194 (57.23) | 61 (81.33) | ||
Mastectomie | 77 (17.38) | 60 (16.76) | 17 (20.24) | 0.4494 | |
Breast surgery Type | Conservative | 366 (82.62) | 298 (83.24) | 67 (79.76) | |
No | 19 (4.45) | 19 (5.51) | 0.0297 | ||
Radiotherapy | Yes | 408 (95.55) | 326 (94.49) | 82 (100.0) | |
No | 126 (28.70) | 116 (32.68) | 10 (11.90) | 0.0007 | |
Chemotherapy | Neoadjuvant | 16 (3.64) | 13 (3.66) | 3 (3.57) | |
Adjuvant | 297 (67.65) | 226 (63.66) | 71 (84.52) | ||
No | 30 (8.72) | 25 (9.06) | 5 (7.35) | 0.6553 | |
Endocrine therapy | Yes | 314 (91.28) | 251 (90.94) | 63 (92.65) | |
No | 261 (85.02) | 208 (84.90) | 53 (85.48) | 0.9081 | |
Trastuzumab | Yes | 46 (14.98) | 37 (15.10) | 9 (14.52) |